SPY425.10+2.50 0.59%
DIA341.98+3.20 0.94%
IXIC14,369.71+97.98 0.69%

Goldman Sachs Initiates Coverage On Recursion Pharmaceuticals with Neutral Rating, Announces Price Target of $34

Goldman Sachs analyst Salveen Richter initiates coverage on Recursion Pharmaceuticals (NASDAQ:RXRX) with a Neutral rating and announces Price Target of $34.

05/11/2021 06:44
Goldman Sachs analyst Salveen Richter initiates coverage on Recursion Pharmaceuticals (NASDAQ:RXRX) with a Neutral rating and announces Price Target of $34.